SCM
CLVS

Stevens Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Stevens Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,741
Closed -$257K – 1128
2017
Q2 		$257K Buy
+2,741
New +$168K 0.01% 710
2014
Q2 		– Sell
-6,134
Closed -$425K – 1374
2014
Q1 		$425K Buy
+6,134
New +$450K 0.01% 705

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Stevens Capital Management's CLVS Position: Q3 2017 in Review

Stevens Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q3 2017, closing a stake of 2,741 shares — an estimated $257K sold.

Stevens Capital Management first reported a position in CLVS in Q1 2014 and held it in 2 quarters. The position peaked at $425K in Q1 2014. 255 funds tracked by Wall St. Rank hold CLVS as of Q3 2017.

  • Stevens Capital Management reported no remaining Clovis Oncology, Inc. position as of Q3 2017 after selling out during the quarter.
  • Stevens Capital Management sold 2,741 Clovis Oncology, Inc. shares in Q3 2017, an estimated $257K.
  • Stevens Capital Management first reported a position in Clovis Oncology, Inc. in Q1 2014 and held it in 2 quarters.
  • Stevens Capital Management's Clovis Oncology, Inc. position peaked at $425K in Q1 2014.
  • 255 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2017.

Based on Stevens Capital Management's 13F filing for Q3 2017, filed 1 Nov 2017.